Stock Markets May 29, 2026 08:30 AM

IFF to Sell Food Ingredients Unit for $4.3 Billion; Shares Rise in Premarket

Deal values unit at about 10x EV/EBITDA as IFF retains 10% stake and plans to redeploy proceeds toward debt reduction, buybacks and growth

By Hana Yamamoto IFF

International Flavors & Fragrances Inc. has reached an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners for approximately $4.3 billion. The transaction, which values the unit at an enterprise value-to-EBITDA multiple of roughly 10x, leaves IFF with a 10% minority equity stake and a board seat in the new company. IFF expects net cash proceeds of about $3.8 billion at closing to be used mainly for debt reduction, targeted share repurchases and reinvestment in growth opportunities. Shares rose 2.5% in premarket trading following the announcement.

IFF to Sell Food Ingredients Unit for $4.3 Billion; Shares Rise in Premarket
IFF

Key Points

  • IFF agreed to sell its Food Ingredients business to funds advised by CVC Capital Partners for approximately $4.3 billion, valuing the unit at about 10x EV/EBITDA.
  • IFF will retain a 10% minority equity interest valued at roughly $200 million and will hold a board seat in the new company; the Food Ingredients business produced nearly $3.1 billion in sales and about $430 million of EBITDA in 2025.
  • Net cash proceeds expected at closing are approximately $3.8 billion and are intended primarily for debt reduction, targeted share repurchases, and reinvestment; the transaction is expected to close by end of Q2 2027, subject to regulatory approvals and customary closing conditions.

International Flavors & Fragrances Inc. (NYSE: IFF) said it has agreed to divest its Food Ingredients business to funds advised by CVC Capital Partners for approximately $4.3 billion, a move that lifted IFF shares about 2.5% in premarket trading on Friday.

The sale places the Food Ingredients unit at an enterprise value-to-EBITDA multiple of approximately 10x. Under the terms, IFF will keep a 10% minority equity interest in the business, a holding the company values at roughly $200 million, and will occupy a seat on the new company’s board.

According to IFF, the Food Ingredients segment generated nearly $3.1 billion in annual sales and delivered about $430 million of EBITDA in 2025. The company said it anticipates receiving net cash proceeds of approximately $3.8 billion at closing. Those proceeds are slated primarily for debt reduction, targeted share repurchases and reinvestment in growth opportunities.

"This transaction represents an important strategic milestone in our ongoing portfolio optimization initiative, allowing us to further concentrate resources on our higher-growth, higher-margin segments," said Erik Fyrwald, chief executive officer of IFF.

Following the divestiture, IFF plans to concentrate on three core businesses - Taste, Scent, and Health & Biosciences - and has reiterated its full-year 2026 outlook. The company maintains guidance for 2026 sales in the range of $10.5 billion to $10.8 billion and adjusted operating EBITDA between $2.05 billion and $2.15 billion.

The transaction is the 13th divestiture completed by IFF in recent years and is part of a broader portfolio reshaping that has generated nearly $10 billion in gross proceeds. The company indicated the deal is expected to close by the end of the second quarter of 2027, subject to regulatory approvals and customary closing conditions.

J.P. Morgan Securities and BofA Securities are serving as IFF’s financial advisors on the transaction.


Market and corporate implications

The sale reduces IFF’s direct exposure to the Food Ingredients business while preserving a minority economic interest and governance representation. The expected net proceeds provide immediate capacity for balance-sheet repair through debt reduction, the possibility of shareholder returns via targeted repurchases, and funds for allocating to higher-growth or higher-margin investments within the remaining portfolio.

Timing and approvals

Closing remains contingent on obtaining regulatory approvals and satisfying customary closing conditions. IFF has set an anticipated close window through the end of the second quarter of 2027 but noted that the timeline depends on those approvals and closing requirements.

Risks

  • The deal is subject to regulatory approvals and customary closing conditions - regulatory or approval delays could affect the timing and certainty of the transaction (impacts M&A and corporate regulatory landscape).
  • The closing is expected by the end of the second quarter of 2027, making timing uncertain and potentially affecting financial planning and market response (impacts corporate finance and equity markets).
  • Receipt and allocation of the projected net cash proceeds of about $3.8 billion depend on the transaction closing as expected - intended uses include debt reduction, share repurchases and reinvestment, which could affect IFF’s capital structure and shareholder returns (impacts debt markets and equity investors).

More from Stock Markets

U.S. Officials Held Early Talks on Taking Equity Stakes in AI Firms, NOTUS Says Jun 4, 2026 Japan Sees Real Wages Climb 1.9% in April; Household Spending Drops Less Than Anticipated Jun 4, 2026 Keystone Acquisition Completes $288.22 Million IPO and Private Warrant Placement Jun 4, 2026 U.S. Futures Slip as Tech Retreats; Markets Await Jobs Report Jun 4, 2026 U.S. Officials Hold Early Talks About Acquiring Equity Stakes in AI Firms Jun 4, 2026